SLB N.V. has been upgraded from neutral to bullish following its Q3 results, which showed better-than-expected revenue and earnings per share. All four divisions improved margins sequentially, with strong performance outside the Middle East. The company projects about $10 billion in Q4 revenue despite flat activity in the Middle East and expects earnings per share to grow 30% year-over-year by 2027. Additionally, SLB's dividend yield has increased to 2.22%, buybacks remain strong, and the recent Kelvion acquisition is anticipated to add value within a year of closing.
SLB stock performance is shown here as of Oct 24, 2026 17:51 WIB. For readers following energy-sector stocks, here is Pluang's market snapshot: out of 79 priced US energy stocks on Pluang, 67 rose and 12 fell today. SLB was priced at USD 53.06 with a 1-day change of +7.08%, typical hold time on Pluang is 100 days, and Pluang order activity was 83% Sell / 17% Buy. Other notable movers include KOS at USD 2.87 (+6.30%) and VIST at USD 74.84 (+5.99%).
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
